Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.
Org chart
Teams
View all
Discover similar companies
Biofrontera
Post IPO Equity • Heidelberg, Germany
Catalyst Pharmaceuticals
Post IPO Equity • Coral Gables, United States
Spectrum Pharmaceuticals
Post IPO Equity • Henderson, United States
DURECT
Post IPO Equity • Cupertino, United States
TRICIDA
Post IPO Equity • South San Francisco, United States
Emmaus Medical
Post IPO Equity • Torrance, United States
4D Pharma
Post IPO Equity • Aberdeen, United Kingdom
Vivesto
Post IPO Equity • Uppsala, Sweden
Insys Therapeutics
Post IPO Equity • Phoenix, United States
Alimera Sciences
Post IPO Equity • Alpharetta, United States
Adamas Pharmaceuticals
Post IPO Equity • Emeryville, United States
Kymera Therapeutics
Post IPO Equity • Watertown, United States
helps you hire
great candidates
It’s free to use - try it out today.